How are KRYS straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the KRYS straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 37.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,908.56 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a KRYS straddle?

The breakeven for the KRYS straddle priced on this page is roughly $290.80 and $349.20 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KRYS market-implied 1-standard-deviation expected move is approximately 10.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current KRYS implied volatility affect this straddle?

KRYS ATM IV is at 37.70% with IV rank near 9.99%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

KRYS Straddle Strategy

KRYS (Krystal Biotech, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

KRYS (Krystal Biotech, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $9.21B, a trailing P/E of 40.68, a beta of 0.50 versus the broader market, a 52-week range of 122.8-317.21, average daily share volume of 304K, a public-listing history dating back to 2017, approximately 275 full-time employees. These structural characteristics shape how KRYS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.50 indicates KRYS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 40.68 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a straddle on KRYS?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current KRYS snapshot

As of May 14, 2026, spot at $315.13, ATM IV 37.70%, IV rank 9.99%, expected move 10.81%. The straddle on KRYS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on KRYS specifically: KRYS IV at 37.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a KRYS straddle, with a market-implied 1-standard-deviation move of approximately 10.81% (roughly $34.06 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KRYS expiries trade a higher absolute premium for lower per-day decay. Position sizing on KRYS should anchor to the underlying notional of $315.13 per share and to the trader's directional view on KRYS stock.

KRYS straddle setup

The KRYS straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KRYS near $315.13, the first option leg uses a $320.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KRYS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KRYS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$320.00	$9.30
Buy 1	Put	$320.00	$19.90

KRYS straddle risk and reward

Net Premium / Debit: -$2,920.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$2,908.56
Breakeven(s): $290.80, $349.20
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

KRYS straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on KRYS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$29,079.00
$69.69	-77.9%	+$22,111.41
$139.36	-55.8%	+$15,143.82
$209.04	-33.7%	+$8,176.24
$278.71	-11.6%	+$1,208.65
$348.39	+10.6%	-$81.06
$418.07	+32.7%	+$6,886.53
$487.74	+54.8%	+$13,854.12
$557.42	+76.9%	+$20,821.70
$627.09	+99.0%	+$27,789.29

When traders use straddle on KRYS

Straddles on KRYS are pure-volatility plays that profit from large moves in either direction; traders typically buy KRYS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

KRYS thesis for this straddle

The market-implied 1-standard-deviation range for KRYS extends from approximately $281.07 on the downside to $349.19 on the upside. A KRYS long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current KRYS IV rank near 9.99% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KRYS at 37.70%. As a Healthcare name, KRYS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KRYS-specific events.

KRYS straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KRYS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KRYS alongside the broader basket even when KRYS-specific fundamentals are unchanged. Always rebuild the position from current KRYS chain quotes before placing a trade.

Frequently asked questions

What is a straddle on KRYS?: A straddle on KRYS is the straddle strategy applied to KRYS (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With KRYS stock trading near $315.13, the strikes shown on this page are snapped to the nearest listed KRYS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are KRYS straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the KRYS straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 37.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,908.56 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a KRYS straddle?: The breakeven for the KRYS straddle priced on this page is roughly $290.80 and $349.20 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KRYS market-implied 1-standard-deviation expected move is approximately 10.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on KRYS?: Straddles on KRYS are pure-volatility plays that profit from large moves in either direction; traders typically buy KRYS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current KRYS implied volatility affect this straddle?: KRYS ATM IV is at 37.70% with IV rank near 9.99%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.